Although recent data from Destiny-Breast04 have shown promising results with T-DXd in HER2-low expressing breast cancers, treatment for patients with HER2-negative (IHC 0) tumors remains a challenge [35,36]. This evidence concerns the gene ERBB2 and breast carcinoma.